首页|期刊导航|癌症生物学与医学(英文版)|Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
Shuyi Hu Ying Liu Tianyi Liu Lin Lu Chengyun Yao Bo Shen Meiqi Shi Cheng Chen Xiaohua Wang Guoren Zhou Zipeng Wu Yingying Dai Xinhong Shi Qin Hu Caolu Liu Yifei Zhu Ruofan Yu Jingwen Li
癌症生物学与医学(英文版)2025,Vol.22Issue(12):1544-1552,9.
癌症生物学与医学(英文版)2025,Vol.22Issue(12):1544-1552,9.DOI:10.20892/j.issn.2095-3941.2025.0393
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
摘要
引用本文复制引用
Shuyi Hu,Ying Liu,Tianyi Liu,Lin Lu,Chengyun Yao,Bo Shen,Meiqi Shi,Cheng Chen,Xiaohua Wang,Guoren Zhou,Zipeng Wu,Yingying Dai,Xinhong Shi,Qin Hu,Caolu Liu,Yifei Zhu,Ruofan Yu,Jingwen Li..Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy[J].癌症生物学与医学(英文版),2025,22(12):1544-1552,9.基金项目
This work was supported by grants from the National Natural Science Foundation of China(Grant No.82273162)and Jiangsu Cancer Hospital Science and Technology Development Fund Project(Grant No.YSZD202409). (Grant No.82273162)